Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesThe Role of OROS Hydromorphone in the Management of Cancer Pain
Pain Practice, 10/27/09
Gardner–Nix J et al. – This review surveys the available literature on the only available once–daily sustained–release formulation of hydromorphone, and its use in cancer pain management. Sustained–release (SR) formulations have a more consistent opioid plasma concentration, thereby minimizing the peaks and troughs associated with immediate–release opioid formulations. OROS hydromorphone (Jurnista, Janssen Pharmaceuticals, NV, Beerse, Belgium) releases hydromorphone over a 24–hour dosing period. Studies comparing its efficacy with other opioids such as morphine and oxycodone found comparable results overall. Recent trials have provided evidence of decreased rescue medication use for breakthrough pain, a good safety profile, and quality of life benefits. It appears to be an efficacious and well–tolerated treatment. The pharmacokinetics of OROS hydromorphone are linear and dose–proportional, and only minimally affected by the presence or absence of food. In addition, the SR properties of OROS hydromorphone are maintained in the presence of alcohol, with no dose dumping of hydromorphone.
Related Articles
An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS hydromorphone in patients with chronic cancer pain
BMC Palliative Care, 10/16/09
Relevance Score: 81%
Core Aspects of Satisfaction with Pain Management: Cancer Patients' Perspectives
Journal of Pain and Symptom Management, 11/02/09
Relevance Score: 68%
Outpatient Continuous Interscalene Brachial Plexus Block in Cancer-Related Pain
Journal of Pain and Symptom Management, 11/03/09
Relevance Score: 67%
Global perspectives on cancer pain
Pain Research and Management, 10/27/09
Relevance Score: 67%
A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial
Current Medical Research and Opinion, 10/08/09
Relevance Score: 67%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome
Diabetes Care, 11/25/09
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/25/09
Antiretroviral Therapy With Heart
American Journal of Therapeutics, 11/25/09
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Axenfeld-Rieger ocular anomaly and retinoblastoma caused by constitutional chromosome 13q deletion
Pediatric Blood & Cancer, 11/25/09
Staphylococcus Aureus Bacteremia in Pediatric Patients With Cancer
The Pediatric Infectious Disease Journal, 11/25/09
Alcohol Consumption and Lung Cancer Risk in the Environment and Genetics in Lung Cancer Etiology (EAGLE) Study
American Journal of Epidemiology, 11/24/09
Article Search
Sponsor